Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trialJörge E. Cortes, Mark J. Levis, Pau Montesinos et al.|The Lancet Oncology|2019Cited by 486